Evaluation of the Risk of NSF Following ProHance Injection in Patients With Chronic Kidney Disease

A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)

NCT07268638 ·Status: RECRUITING ·Phase: PHASE2

A Study to Evaluate PF-06730512 in Adults With Focal Segmental Glomerulosclerosis (FSGS)

NCT03448692 ·Status: TERMINATED ·Phase: PHASE2

Predictive Determinants of Nephrotic Syndrome Remission in Patients With At-risk Polymorphism of APOL1

NCT06443034 ·Status: NOT_YET_RECRUITING

A Study to Evaluate the Effect of Tacrolimus and Corticosteroid Combination Therapy in Patients With Minimal Change Nephrotic Syndrome

NCT01763580 ·Status: COMPLETED ·Phase: PHASE4

Soluble Neprilysin, NT-proBNP, and Growth-Differentiation-Factor-15 as Biomarkers for Heart Failure in Dialysis Patients

NCT04061811 ·Status: COMPLETED

Nephrotic Syndrome Study Network

NCT01209000 ·Status: RECRUITING

Safety Study of GC1008 in Patients With Focal Segmental Glomerulosclerosis (FSGS) of Single Doses of GC1008 in Patients With Treatment Resistant Idiopathic FSGS

NCT00464321 ·Status: COMPLETED ·Phase: PHASE1

Study on Efficacy and Safety of LNP023 in C3 Glomerulopathy Patients Transplanted and Not Transplanted

NCT03832114 ·Status: COMPLETED ·Phase: PHASE2

A Study of CCX140-B in Subjects With Primary FSGS and Nephrotic Syndrome

NCT03703908 ·Status: TERMINATED ·Phase: PHASE2

A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)

NCT01665391 ·Status: COMPLETED ·Phase: PHASE2

Safety and Pharmacokinetics of FG-3019 in Adolescents and Adults With Focal Segmental Glomerulosclerosis (FSGS)

NCT00782561 ·Status: TERMINATED ·Phase: PHASE1

Prospective, Multicenter Study of the Efficacy and Tolerance of Tacrolimus on Refractory Nephrotic Syndrome (RNS)

NCT00615667 ·Status: COMPLETED ·Phase: PHASE3

A Renal Impairment Study for PF-04965842

NCT03660241 ·Status: COMPLETED ·Phase: PHASE1

Natural History and Structural Functional Relationships in Fabry Renal Disease Treatment Outcomes(Changes)in Fabry Renal Disease Study

NCT01581424 ·Status: RECRUITING

A Phase 1 Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ManNAc in Subjects With Primary Podocyte Diseases

NCT02639260 ·Status: COMPLETED ·Phase: PHASE1

Renal Impairment Study of PF-06700841

NCT04260464 ·Status: COMPLETED ·Phase: PHASE1

Use of Acthar in Patients With FSGS That Will be Undergoing Renal Transplantation

NCT02683889 ·Status: COMPLETED ·Phase: PHASE3

Inflammatory and Immune Profiling of Kidney Tissue Obtained From Patients With Newly Diagnosed Kidney Disease

NCT01156428 ·Status: COMPLETED

Permeability Factor in Focal Segmental Glomerulosclerosis

NCT00007475 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Pilot Studies of Novel Therapies to Treat Resistant Focal Segmental Glomerulosclerosis (FSGS)

NCT00193648 ·Status: COMPLETED ·Phase: PHASE1

Paricalcitol in Fabry Disease

NCT02090608 ·Status: COMPLETED ·Phase: NA

A Phase 1 Study to Assess the Effect of Severe Renal Impairment on the Pharmacokinetics, as Well as Safety/Tolerability, of Ranolazine

NCT01675973 ·Status: TERMINATED ·Phase: PHASE1

Primovist / Eovist in Renally Impaired Patients

NCT00908596 ·Status: COMPLETED ·Phase: PHASE4

Phase II Randomized, Open-label, Multicenter Clinical Study Evaluating the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of SHR-2173 Injection in Patients With Primary Membranous Nephropathy

NCT07289763 ·Status: RECRUITING ·Phase: PHASE2

Effects of a Non-Calcium Based Phosphate Binder on FGF23 Levels in Chronic Kidney Disease

NCT01308242 ·Status: COMPLETED ·Phase: EARLY_PHASE1